In this Demystifying Medicine video from McMaster University, learn more about idiopathic pulmonary fibrosis (IPF), a scleroderma-related condition that currently has no known cause.
Back in February, researchers presented a study investigating the therapeutic effect of the monoclonal antibody CM-101 in animal models of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF).
According to the Scleroderma Foundation, pulmonary disease is an important component of systemic sclerosis (SSc). Approximately 80% of patients with SSc have some evidence of pulmonary disease.
Scleroderma News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?